Datametrex Secures Rights To Sell And Distribute Rapid COVID-19 Antigen Test Kits

Datametrex AI (TSXV: DM) this morning announced that it has secured the rights to sell and distribute a rapid antigen detection kit from South Korean manufacturer PCL Inc. The main benefit of the test is that with 97% accuracy, they produce results in as little as 5 to 10 minutes with no extra equipment being required for the consumer.

Datametrex AI's Logo

The test hosts advantages over others on the market solely as a result of the rapid testing nature of the product, combined with the lack of additional equipment being needed to conduct the test. The test is a method of measuring the presence of a COVID-19 infection via an in-vitro diagnostic medical device. It detects antigen of the SARS-CoV-2 virus from a persons oropharyngeal and nasopharyngeal secretions. Like a simple pregnancy test, if antigens are found a colored line appears in the T line area.

It’s said that the test has a clinical sensitivity, i.e., the ability to confirm the actual positive of the approved person, of 100%, and the clinical specificity, i.e the ability to confirm the actual negative of the negative person, of 97.78%. The antigen test has been awarded numerous certifications, including CE, Korea FDA, UNGM and more. It’s also been approved by the EU, Qatar, United Arab Emirates, India, Russia, Ecuador, Guatemala and Colombia.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy. These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

Marshall Gunter, CEO of Datametrex

The strong benefit of the instant antigen kits that require no additional equipment, is that they can be conducted at home easily, with nearly instant results. This eliminates excessive wait times as high as 3-5 days or more previously experienced by individuals that have had other forms of COVID-19 tests performed.

Datametrex AI last traded at $0.15 on the TSX Venture.


FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Republicans Reveal Details of $1 Trillion Second Coronavirus Relief Package, Americans Slated to Receive Another $1,200 Payment

After various struggles that delayed the the unveiling of the much anticipated second coronavirus relief...

Monday, July 27, 2020, 02:58:32 PM

Food Shortages May Become Reality Amid Coronavirus Pandemic

The global coronavirus pandemic has wreaked havoc across economies, closing down businesses, putting millions out...

Friday, April 24, 2020, 07:50:33 AM

Coronaviral! Market Movers Takes On The Low-Float Pandemic Pops

There’s no panic like a pandemic. Equities markets of all kinds took another tumble Friday...

Saturday, February 29, 2020, 11:37:57 AM

Dr. Fauci Issues Grim Forecast for US Coronavirus Outbreak, Daily New Cases Could Reach 100,000

As the coronavirus pandemic continues to spiral out of control south of the border, White...

Wednesday, July 1, 2020, 05:14:00 PM

Datametrex Raises COVID-19 Test Kit Guidance To $50 Million For 2021 From Single Client

In a rare move within the small cap space, Datametrex AI (TSXV: DM) has provided...

Tuesday, September 14, 2021, 07:55:56 AM